The document outlines the procedures established by the Department of Defense (DoD) regarding the formulary placement of newly approved innovator drugs under the TRICARE Pharmacy Benefits Program. Published on July 27, 2015, the final rule permits the Pharmacy and Therapeutics (P&T) Committee up to 120 days to recommend the tier placement for FDA-approved innovator drugs categorized as new molecular entities, new active ingredients, new dosage forms, or new combinations. Innovator drugs approved after August 26, 2015, will initially have a “pending” status and be subject to non-formulary availability. The document specifies that cost-effectiveness analyses will guide the tier designations (Tier 1 to Tier 4/Not Covered) at quarterly P&T meetings, where drug pricing information must be submitted within specified solicitation windows. Notably, innovator drugs designated as Tier 3 will not generally be available at Military Treatment Facilities (MTFs) unless medical necessity is demonstrated by a prescriber. Furthermore, due to the high volume of newly approved drugs, the DoD will not accept clinical presentations from pharmaceutical manufacturers for these innovator drugs. Overall, the rule aims to streamline the drug evaluation process while ensuring cost-effective healthcare delivery for military personnel and their families.

This document is a Price Appendix FAQ related to federal RFPs for drug pricing and formulary submissions, outlining procedures for entering drug pricing information in a spreadsheet. It covers three main sections: BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). Each section emphasizes the importance of reading the Formulary Notes to understand the P&T committee’s decision-making process. Respondents must fill out designated yellow cells while other fields are locked for editing. Automatic calculations assist in determining Price per Unit, Total Calculated Refund, and Total Calculated Retail Refund. Instructions include guidelines for submitting fewer or more than the standard number of National Drug Codes (NDCs), contacting Points of Contact (POCs) for queries, and indicating non-submissions by the highlighting of specific cells. This document serves to streamline the process of drug quote submissions for formulary consideration in a structured and organized manner, ensuring compliance with federal requirements.

The Department of Defense (DoD) is preparing for a Pharmacy and Therapeutics (P&T) Committee meeting scheduled for February 5-6, 2025, focusing on new neurological agents. Quotes for these newly approved drugs are due by January 16, 2025, with specific attention to both Uniform Formulary and Non-Formulary classifications. The document outlines various drugs categorized as 'Neurological Agents Miscellaneous,' indicating that prior authorization may apply and special reimbursement methods could encourage high-value products while deterring low-value alternatives. Manufacturers are advised to submit fully executed documents along with their quotes, establishing a mandatory verification step if a quote is not provided. The P&T Committee's role includes reviewing candidates for preferential status, which may include treating certain agents as generic products for cost-sharing purposes or recommending complete exclusion from the TRICARE pharmacy benefit program. This document serves as a guideline for drug manufacturers intending to participate in the DoD's formulary and reimbursement processes, underscoring the importance of compliance as well as strategic pricing in a highly regulated governmental environment.

The document outlines the details concerning the Department of Defense's (DOD) upcoming Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025, focusing on the review of oncological agents. It specifies that quotes for newly approved drugs must be submitted by January 16, 2025. Each section within the document presents listings for drugs categorized as either Uniform Formulary or Non-Formulary, with specific identifiers (NDC numbers) but currently lacking submitted quotes. Additionally, guidelines include notes on the potential for prior authorization, step therapy considerations, and discount program information aimed at enhancing the use of high-value pharmaceutical products within the TRICARE system. The document emphasizes the need for manufacturers to include completed signature pages with their quotes. It also reflects the DOD's strategic approach to manage pharmaceutical expenditures and ensure access to necessary medications for military beneficiaries, while adhering to federal regulations regarding drug pricing and reimbursement within the pharmacy benefit program. Overall, it serves as a call to action for pharmaceutical providers looking to navigate the DOD formulary processes successfully.

The Department of Defense's (DoD) P&T Committee is scheduled to review new antibiotics within the tetracycline subclass during meetings on February 5-6, 2025. Quotes for these newly approved drugs are due January 16, 2025. The document outlines a Blanket Purchase Agreement for multiple drugs, indicating scenarios with pricing and categorization as either uniform or non-formulary. Additionally, the document emphasizes the need for manufacturers to confirm their intent to submit quotes, with opportunities for additional discounts through TRICARE retail refunds. Key points include the potential for prior authorization on selected agents, and the use of high-value products over low-value alternatives is encouraged. The P&T Committee may grant preferential cost-sharing status to certain non-generic products while also identifying candidates for exclusion from TRICARE benefits. Overall, this process underlines the DoD's efforts to enhance pharmaceutical procurement for military healthcare, adhering to regulatory requirements while focusing on cost-effectiveness and strategic use of available drugs.

The document outlines critical information regarding the Department of Defense (DoD) Uniform Formulary Class for Antihemophilic Factors, set for review at the P&T Committee Meeting scheduled for February 5-6, 2025. Quotes from vendors are due by January 16, 2025. Each newly approved drug is categorized as either Uniform Formulary (UF) or Non-Formulary with no quotes submitted thus far. The document emphasizes that the P&T Committee may suggest various reimbursement methods aimed at promoting the use of high-value products while discouraging low-value choices. It includes necessary details for manufacturers, such as the requirement to submit signed quote information. Additionally, the document stipulates possible scenarios based on drug classifications and tier levels, with potential impacts on retail refund structures under the TRICARE program. This initiative reflects the DoD's ongoing efforts to manage pharmaceutical benefits while ensuring appropriate cost-sharing measures and overall compliance with federal regulations.

The document outlines the requirements and considerations for the Department of Defense (DoD) regarding the procurement of white blood cell stimulants, specifically filgrastims, in preparation for the Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025. Quotes for these products are due by January 16, 2025. It highlights the Uniform Formulary Class, detailing price considerations and formulary scenarios for various agents, both before and after therapy steps, emphasizing the importance of cost sharing in pharmaceutical management. Agents with certain cost thresholds may either be favored or excluded based on their pricing compared to established benchmarks. The document also instructs manufacturers to include all requisite signature pages with their quotes and provides guidance on the pricing structure, including the Wholesale Acquisition Cost (WAC) and potential refunds under the TRICARE system. It emphasizes the necessity for prior authorization processes and the encouragement of high-value product usage to optimize benefits within the pharmaceutical pipeline. This emphasis on pricing strategy and formulary management reflects the DoD's commitment to maintaining operational efficiency and cost-effectiveness in military healthcare.

The Department of Defense (DOD) is preparing for the upcoming Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025. The focus of this meeting will be on the Uniform Formulary Class of Insulins, specifically within the subclass of Miscellaneous Insulin Devices. Vendors are required to submit quotes by January 16, 2025, for newly approved drugs under this category. The document outlines the pricing parameters including National Drug Codes (NDC), dosage forms, and potential pricing scenarios, indicating that no quotes have been received for various uniform and non-formulary drugs. It emphasizes that prior authorizations may apply to certain agents and notes that the P&T Committee may recommend preferential treatment for specific pharmaceutical agents or their exclusion from the TRICARE pharmacy benefit. Additional considerations also include the establishment of discount programs and reimbursements aimed at enhancing the use of high-value medications. This document is part of the DOD’s systematic approach to managing pharmaceutical benefits, demonstrating a commitment to cost control while ensuring accessibility to necessary medications for military beneficiaries. The structured process assists in evaluating new drugs for Medicaid and reimbursement eligibility under federal regulations.

The Department of Defense (DOD) is preparing for the upcoming Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025, focusing on oncological agents. A call for quotes from manufacturers is due by January 16, 2025, for various newly approved drugs under the DOD Uniform Formulary, which categorizes the drugs as either Uniform or Non-Formulary with no quotes submitted thus far. The document details price and dosage specifications alongside policies regarding potential prior authorization and reimbursement methods aimed at promoting high-value medications while discouraging less effective options. The P&T Committee may also consider granting preferential status to certain non-generic agents and identifying drugs for exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit complete quote documentation, including signature pages, and notes regarding the wholesale acquisition costs and additional refund policies are outlined. Overall, the documentation reflects the DOD's structured approach to evaluating and updating its pharmaceutical marketplace to ensure optimal healthcare for military beneficiaries while adhering to regulatory standards.

The Department of Defense (DOD) issued a Request for Quotation (RFQ) for pharmaceuticals as part of its Uniform Formulary (UF) program, necessitating effective and integrated pharmacy benefits for the Military Health System (MHS). Under this initiative, the DOD Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost-effectiveness of pharmaceutical agents. Manufacturers can submit offers to reduce costs or provide discounts through Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP). Key instructions outline the submission process, including downloading necessary datasets, sending signed quotes, and responding to specific clinical questions about new drugs. The document stipulates detailed pricing conditions and evaluations, emphasizing that multiple price quotes might be required depending on the selected pharmaceuticals. Acceptance of quotes will depend on recommendations from the P&T Committee and decisions from the Defense Health Agency (DHA) Director. The document establishes a framework for pricing, discount requirements, and refund protocols, reflecting the DOD's effort to optimize pharmaceutical procurement while ensuring compliance with federal regulations. Overall, the RFQ serves as a critical component in maintaining cost-effective and accessible health services for DOD beneficiaries while fostering collaboration with pharmaceutical companies.